Pharmaceutical Business review

Genizon, NDEI partner for schizophrenia study

Genizon’s study identified multiple genes associated with the disease using DNA samples from patients from the Quebec founder population.

Michel Maziade, professor of psychiatry at the University of Laval, said: “Schizophrenia is a truly devastating disease for both those afflicted and their families. We expect the results of these studies to lead to a new generation of safer and more effective treatments tailored to individual schizophrenia patients. We are thrilled to be collaborating with Genizon to achieve this goal.”